GSK plc (NYSE:GSK) Shares Bought by EP Wealth Advisors LLC

EP Wealth Advisors LLC raised its stake in GSK plc (NYSE:GSK) by 14.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,605 shares of the pharmaceutical company’s stock after purchasing an additional 1,490 shares during the quarter. EP Wealth Advisors LLC’s holdings in GSK were worth $474,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Kovitz Investment Group Partners LLC lifted its holdings in shares of GSK by 46.8% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 20,024 shares of the pharmaceutical company’s stock valued at $819,000 after acquiring an additional 6,383 shares in the last quarter. Taika Capital LP acquired a new position in shares of GSK during the 3rd quarter valued at $1,028,000. Stifel Financial Corp lifted its holdings in shares of GSK by 9.7% during the 3rd quarter. Stifel Financial Corp now owns 604,973 shares of the pharmaceutical company’s stock valued at $24,731,000 after acquiring an additional 53,440 shares in the last quarter. IHT Wealth Management LLC lifted its holdings in shares of GSK by 49.6% during the 3rd quarter. IHT Wealth Management LLC now owns 24,929 shares of the pharmaceutical company’s stock valued at $1,015,000 after acquiring an additional 8,266 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after acquiring an additional 833,080 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

GSK opened at $34.17 on Friday. The company has a 50-day moving average of $36.36 and a 200-day moving average of $39.40. The company has a market capitalization of $70.81 billion, a P/E ratio of 22.19, a PEG ratio of 1.33 and a beta of 0.64. GSK plc has a 1-year low of $32.83 and a 1-year high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a $0.3928 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.60%. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is presently 98.70%.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GSK. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.